Prediction of mortality in adult patients with severe acute lung failure receiving veno-venous extracorporeal membrane oxygenation: a prospective observational study by Tone Enger et al.
Enger et al. Critical Care 2014, 18:R67
http://ccforum.com/content/18/2/R67RESEARCH Open AccessPrediction of mortality in adult patients with
severe acute lung failure receiving veno-venous
extracorporeal membrane oxygenation: a
prospective observational study
Tone Bull Enger4, Alois Philipp1, Vibeke Videm4,7, Matthias Lubnow2, Alexander Wahba5,6, Marcus Fischer2,
Christof Schmid1, Thomas Bein3 and Thomas Müller2*Abstract
Introduction: Veno-venous extracorporeal membrane oxygenation (vvECMO) can be a life-saving therapy in patients
with severe acute lung failure refractory to conventional therapy. Nevertheless, vvECMO is a procedure associated with
high costs and resource utilization. The aim of this study was to assess published models for prediction of mortality
following vvECMO and optimize an alternative model.
Methods: Established mortality risk scores were validated to assess their usefulness in 304 adult patients undergoing
vvECMO for refractory lung failure at the University Medical Center Regensburg from 2008 to 2013. A parsimonious
prediction model was developed based on variables available before ECMO initiation using logistic regression
modelling. We then assessed whether addition of variables available one day after ECMO implementation
enhanced mortality prediction. Models were internally validated and calibrated by bootstrapping (400 runs).
Predictive ability, goodness-of-fit and model discrimination were compared across the different models.
Results: In the present study population, existing mortality prediction tools for vvECMO patients showed suboptimal
performance. Evaluated before vvECMO initiation, a logistic prediction model comprising age, immunocompromised
state, artificial minute ventilation, pre-ECMO serum lactate and hemoglobin concentrations showed best mortality
prediction in our patients (area under curve, AUC: 0.75). Additional information about norepinephrine dosage, fraction
of inspired oxygen, C-reactive protein and fibrinogen concentrations the first day following ECMO initiation further
improved discrimination (AUC: 0.79, P = 0.03) and predictive ability (likelihood ratio test, P < 0.001). When classifying
patients as lower (<40%) or higher (>80%) risk based on their predicted mortality, the pre-ECMO and day1-on-ECMO
models had negative/positive predictive values of 76%/82% and 82%/81%, respectively.
Conclusions: While pre-ECMO mortality prediction remains a challenge due to large patient heterogeneity, evaluation
one day after ECMO initiation may improve the ability to separate lower- and higher-risk patients. Our findings support
the clinical perception that chronic health condition, high comorbidity and reduced functional reserves are strongly
related to survival during and following ECMO support. Renewed evaluation the first day after ECMO initiation may
provide enhanced guidance for further handling of ECMO patients. Despite the usefulness of prediction models,
thorough clinical evaluation should always represent the cornerstone in decision for ECMO.* Correspondence: thomas.mueller@ukr.de
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For more than 40 years, veno-venous extracorporeal mem-
brane oxygenation (vvECMO) has been used in critically ill
patients with reversible acute lung failure (ALF). Following
major improvements in ECMO technology and safety, the
survival benefit shown in the CESAR trial [1], the useful-
ness of ECMO support during the influenza-A/H1N1-virus
epidemic in 2009 to 2010 [2] and the increasing evidence
that early ECMO may help to avoid substantial lung and
consecutive organ injury [3-5], ECMO is now implemented
more frequently and in a broader spectrum of patients.
Objective risk assessment is a valuable tool to aid the
selection of therapeutic approach, to compare ECMO
practice and success rates across different ECMO cen-
ters and to provide relatives with objective information
about the patient's condition. Thus, there has been an
increasing interest in identifying important prognostic
factors for vvECMO. Published work includes two risk
scores designed for pre-ECMO mortality prediction in
patients with acute respiratory distress syndrome (ARDS),
the ECMOnet score [6] and the PRESERVE score [7].
Presently, it is thought that multi-organ failure and
sepsis play a more important role than the patient’s
hemodynamic and respiratory state in the acute situation
[6,8,9]. However, findings have been inconsistent. Limi-
tations of previous studies include changes in ECMO
technology and procedure over time, small study popu-
lations, large patient heterogeneity, limited registration
of potentially important factors related to outcome, and
application of statistical methods which may not take
into account the random variability of patients, thus
leading to results that have not been reproducible.
A large study population, application of up-to-date
statistical methods designed to avoid overfitting and
use of thorough internal and external validation are
crucial steps in the development of reproducible ECMO
risk scores to be integrated in clinical practice. Based
on prospectively collected data from an institution where
different forms of ECMO are now performed more than
100 times per year, we validated the existing risk scores
and compared their predictive ability with the more
general Sequential Organ Failure Assessment (SOFA)
score frequently used in the intensive care unit (ICU).
Furthermore, in accordance with the hypothesis that
ECMO outcome is largely dependent on the patient’s
extra-pulmonary status and general health condition, our
aim was to examine data regarding clinical characteristics,
respiratory and laboratory parameters, to develop two
novel risk scores: one designed for pre-ECMO mortality
prediction and one including parameters measured
one day after ECMO implantation. We compared the
different pre-ECMO mortality prediction models and
investigated whether day 1 parameters could enhance
predictive ability.Materials and methods
From 1 January 2008 to 15 July 2013, vvECMO was ini-
tiated in 304 consecutive adults with ALF refractory to
conventional therapeutic modalities at the University Med-
ical Center Regensburg (UKR), Germany. The general
indication for vvECMO was either a ratio of partial arter-
ial pressure of oxygen/fraction of inspired oxygen (PaO2/
FiO2) <80 mmHg on a positive end-expiratory pressure
of ≥16 cm H2O, or a refractory respiratory acidosis
(pH <7.25), despite optimization of conservative therapy.
The ECMO circuit consisted of a centrifugal pump and
a coated polymethylpentene oxygenator. In 99% of the
patients, cannulation was performed percutaneously with
Seldinger’s technique. In 75%, single-lumen cannulas were
implemented with blood-flow from the femoral vein and
to the jugular (80%), subclavian (15%) or contralateral
femoral (4%) vein. Nineteen percent and six percent of the
patients received a single double-lumen jugulo-jugular
(Avalon Elite®, MAQUET Holding B.V. & Co KG, Rastatt,
Germany) and femoro-femoral (Novaport® twin, Novalung
GmbH, Heilbronn, Germany) cannula, respectively. Fur-
ther ECMO settings and patient management followed an
institutional protocol as described previously [8].
Clinical data regarding pre-, intra- and post-ECMO char-
acteristics and functions were prospectively registered
in the UKR ECMO database. More detailed method
descriptions are given in Additional file 1. All patients
were followed up until in-hospital death (non-survi-
vors) or hospital discharge (survivors). The study was
approved by the local ethical committee of the UKR
(reference number: 14-180-0051). The requirement for
individual patient consent was waived as this study was
based on anonymized data from routine care.
Statistical analysis
Data are given as median (95% confidence intervals; CI)
for continuous variables, and as frequency (percentage) for
categorical variables. The Mann Whitney U-test and χ2 test
were used to investigate differences between survivors and
non-survivors for continuous and categorical variables,
respectively. All tests were two-sided and P-values ≤0.05
were considered significant. Cases with missing values
were excluded from the analyses. Statistical analyses were
performed using SPSS (version 21.0, SPSS Inc., Chicago,
IL, USA), Stata (version 12.1, StataCorp LP, College
Station, TX, USA), SigmaPlot (version 12.0, Systat Soft-
ware, Inc., San Jose, CA, USA), Minitab (version 15.1.30,
Minitab Inc., State College, PA, USA) and the ‘rms’,
‘Hmisc’, ‘xtable’ and ‘party’ packages of R statistical soft-
ware (version 3.0.1, R Foundationa).
Validation of external risk scores
The external scores were tested in the present patient
population as described in the original publications (see
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during data collection and stored in the database. ECM-
Onet and PRESERVE scores were calculated retrospect-
ively. We found matching definitions for all variables
except plateau pressure, which was not registered in
our database due to the mode of mechanical ventilation
used. Peak inspiratory pressure was used as a substitute.
The discriminative abilities of the external risk scores were
assessed by the area under the receiver-operating charac-
teristics curves (AUC). Since poor fit may be explained
by substantial differences in the study populations, pre-
dictors identified by the two scores were recalibrated
using multivariate logistic regression analyses. The original
estimates for the linear predictor variables, on which the
additive ECMOnet and PRESERVE scores were based,
were compared with the recalibrated coefficients and odds
ratios, respectively. Clinical usefulness was evaluated using
information from the original studies. For the ECMOnet
score, we compared the sensitivity and specificity in our
population using the authors’ proposed cut-off score for
mortality of >4.5 as well as the estimated optimal cut-off
in our population, calculated by the Youden index [10].
For the PRESERVE score, we compared mortality rates
across groups of PRESERVE scores as described in the
original study. We used a simple prognostic separation
index (PSEP) to estimate the ability of the score to separ-
ate individuals into prognostic groups and compared the
index across the cohorts to evaluate the reproducibility
in new patients [11].
Model 1: Pre-ECMO mortality prediction
Variable selection for prediction of in-hospital death com-
bined literature review, clinical experience and hypotheses
of potential influences on ECMO outcome as well as
computer-based modelling (Additional file 3). A final
parsimonious model was derived using logistic regression
on the full dataset (n = 304), and further validated using
bootstrap resampling with replacement (400 runs). Pre-
dicted probabilities of mortality were calculated based on
bootstrapped coefficients (400 runs). Model performance
was evaluated by plotting observed probabilities across
deciles of predicted risk. Model discrimination was
assessed with AUC, goodness-of-fit with a Hosmer-
Lemeshow (HL) test, model overfitting by calculation of
the shrinkage factor, and calibration by a calibration plot.
The novel risk model was compared with the ECMOnet,
PRESERVE and SOFA scores (Additional file 1).
Model 2: Mortality prediction on day 1
For the second model, we added variables available one
day after ECMO initiation to the final pre-ECMO model.
The procedure of variable selection, validation and cali-
bration of the final model was performed as described
for Model 1. Models 1 and 2 were compared statisticallyby a likelihood ratio (LR) test. A simultaneous comparison
of discrimination for all models (n = 241) was performed
using the method for non-parametric correlated AUCs as
proposed by DeLong et al. [12]. The novel day 1 risk
model was also compared with the ECMOnet, PRESERVE
and SOFA scores calculated with day 1 data (n = 236).
Clinical usefulness of the two novel models was evalu-
ated by dividing the cohort into three groups based on
predicted mortality risks: low (<40%), moderate (40% to
80%) and high (>80%) (Additional file 1). A simple PSEP
was calculated to address separation between the lowest
and highest risk groups. Negative and positive predictive
values were calculated for the lowest and highest risk
groups, respectively, as a measure of clinical validity.
Results
Study population
Overall survival until hospital discharge was 61.5%; 81
patients (27%) died during mechanical support and 36
patients (12%) died after weaning from ECMO. The best
outcome was noted in trauma patients (74%), followed by
primary lung failure (66%), extra-pulmonary lung failure
and other causes (both 50%). Before ECMO initiation,
non-survivors were longer hospitalized, had higher serum
lactate concentrations, lower hemoglobin concentrations
and more frequently showed signs of additional organ
dysfunctions (pre-ECMO need for continuous veno-venous
hemofiltration, higher bilirubin and liver enzyme concen-
trations). PaO2/FiO2, commonly used in the classification
of ARDS severity, did not differ significantly between
survivors and non-survivors. On the first day on ECMO,
non-survivors showed less improvement of their respi-
ratory failure, with higher minute ventilation, persisting
low oxygenation and higher norepinephrine dosages. A
comparison of survivors and non-survivors is given in
Table 1 and Additional file 4.
Performance of external risk prediction models in
our population
Both the ECMOnet and PRESERVE scores showed limited
discrimination (AUC <0.70) and poor goodness-of-fit in
our population (Table 2). Recalibration of the predictor
variables of the ECMOnet score revealed substantial dif-
ferences in the coefficients of the validation and original
study cohorts (data not shown). Discrimination was not
improved by recalibration. The proposed cut-off score for
mortality >4.5 yielded a sensitivity and specificity of 58%
and 53%, respectively. The optimal cut-off for mortality in
our population was >5.0, giving a sensitivity and specificity
of 52% and 65%, respectively. For the PRESERVE score,
the observed mortality rates for score classes 0 to 2, 3 to
4, 5 to 6 and ≥7 showed an increasing trend as in the
original study; however, the rates were higher for the
lower-risk groups and lower for the higher-risk groups
Table 1 Comparison of survivors and non-survivors after ECMO
Non-survivors (n = 117) Survival to discharge (n = 187) P-value
Baseline clinical characteristics
Age (years) 54 (50 to 57) 46 (43 to 48) <0.001
Immunocompromised statea 37 (31.6%) 26 (13.9%) <0.001
Sequential organ failure assessment score 13 (12 to 14) 11 (11 to 12) 0.001
Continuous veno-venous hemofiltration pre-ECMO 45 (38.5%) 36 (19.3%) <0.001
Classification of acute lung injuryb 0.022
− Group 1: Pulmonary 56 (47.9%) 107 (57.2%)
− Group 2: Extra-pulmonary 36 (30.8%) 36 (19.3%)
− Group 3: Trauma 10 (8.6%) 29 (15.5%)
− Group 4: Others 15 (12.8%) 15 (8.0%)
Pre-ECMO duration (days) of
− Hospitalization 10 (8 to 12) 5 (4 to 7) 0.023
− Mechanical ventilation 5 (3 to 7) 2 (2 to 3) 0.013
Baseline cardiorespiratory parameters
Minute ventilation (L/minute) 11.2 (10.6 to 12.0) 10.4 (10.0 to 10.9) 0.038
Baseline laboratory parameters
Lactate (mmol/L) 38 (30 to 47) 23 (20 to 27) 0.002
Lactate dehydrogenase (U/L) 510 (446 to 608) 452 (408 to 499) 0.076
Bilirubin (mg/dL) 1.2 (0.9 to 1.6) 0.9 (0.8 to 1.1) 0.060
ASAT (U/L) 122 (96 to 159) 78 (65 to 96) 0.005
Hemoglobin (g/dL) 9.8 (9.4 to 10.3) 10.9 (10.5 to 11.3) <0.001
D-dimer (mg/L) 11 (9 to 14) 8 (7 to 10) 0.022
Procedural characteristics of ECMO treatment
Transport-ECMO (no/yes) 34 (29.1%) 99 (52.9%) <0.001
Red cell transfusions (about 320 mL) per patient 8 (6 to 9) 3 (3 to 4) <0.001
Plasma transfusions (about 250 mL) per patient 3 (2 to 5) 0 (0 to 1) 0.001
Platelet transfusions (about 270 mL) per patient 1 (0 to 1) 0 (0 to 0) <0.001
Laboratory and cardiorespiratory status after one day on ECMO
Minute ventilation (L/minute) 5 (5 to 6) 4 (4 to 5) 0.011
Tidal volume (mL) 305 (278 to 332) 278 (262 to 294) 0.097
Norepinephrine infusion (μg/minute/kg) 0.18 (0.13 to 0.25) 0.12 (0.09 to 0.14) 0.041
Blood gas analysis
− FiO2 (%) 65 (60 to 68) 55 (52 to 58) <0.001
− PaO2/FiO2 (mmHg) 122 (112 to 133) 146 (137 to 155) <0.001
Laboratory parameters
− Lactate (mmol/L) 36 (27 to 47) 24 (21 to 28) 0.002
− C-reactive protein (mg/L) 162 (143 to 180) 214 (196 to 231) <0.001
− Bilirubin (mg/dL) 1.9 (1.5 to 2.3) 1.1 (1.0 to 1.3) 0.015
− Lactate dehydrogenase (U/L) 584 (502 to 717) 511 (462 to 573) 0.054
− International normalized ratio 1.38 (1.32 to 1.48) 1.27 (1.24 to 1.31) 0.002
Continuous variables are shown as median (95% confidence interval), categorical variables as n (%). Differences for survivors and non-survivors are shown for
P <0.1. A wider comparison can be seen in Additional file 4. aImmunocompromised state included hematological malignancies, solid tumors, solid organ transplantation,
high-dose or long-term corticosteroid or other immunosuppressive therapy, or human immunodeficiency virus infection. bGroup 1: primary lung failure, including bacterial,
viral, fungal or aspiration pneumonia; Group 2: extra-pulmonary sepsis with secondary lung injury; Group 3: multiple trauma with ARDS; Group 4: other
pathologies, including near drowning, chronic lung diseases, such as lung fibrosis and lung transplantation. ASAT, aspartate aminotransferase; ECMO,
extracorporeal membrane oxygenation; FiO2,fraction of inspired oxygen; PaO2/FiO2, ratio of partial arterial oxygen pressure/fraction of inspired oxygen;
SOFA, Sequential Organ Failure Assessment.
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Table 2 Comparison of mortality prediction models in the study population (number = 304)
Model Valid n AUC P-valuea Hosmer-Lemeshow test P-value
Pre-ECMO prediction
SOFA score 303 0.611 (0.544-0.678) 0.027 <0.0001b
ECMOnet score 280 0.604 (0.537-0.671) 0.009 0.0002b
PRESERVE 289 0.685 (0.623-0.748) 0.12 0.004b
Model 1 284 0.746 (0.689-0.804) Reference 0.50
Day 1 prediction
Model 2 263 0.786 (0.730-0.843) 0.026 0.73
aPairwise comparisons of AUCs with Model 1 using DeLongs method (n = 241) [12]. bModified Hosmer-Lemeshow test comparing grouped mortality risk against
the deciles of Model 1 predictions. AUC, area under receiver operating characteristics curve; ECMO, extracorporeal membrane oxygenation; SOFA, Sequential
Organ Failure Assessment.
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reduced from 0.81 in the original analysis to 0.53,
although the overall mortality rates were similar. Recali-
bration gave minimal differences in the coefficients of the
validation and original study cohort (data not shown).
Neither the ECMOnet nor the PRESERVE score showed
enhanced discrimination compared to the SOFA score
(P = 0.67 and P = 0.25, respectively, Figure 1).
Novel risk prediction models
Model 1
The final pre-ECMO mortality prediction model con-
tained five variables (Table 4). A plot of observed mor-
tality against increasing deciles of predicted mortality
risk showed good predictive ability, although the
model tended to overestimate mortality in patients
with predicted risk between 18% and 23% (third decile
group, Additional file 5). The prediction model showed
acceptable discrimination (AUC >0.70 but <0.80), a
good goodness-of-fit (HL test, P = 0.50) and had a
shrinkage factor of 0.83.
Comparison of pre-ECMO prediction models The
mortality risk predicted by the external scores did not
adequately fit with the observed mortality (modified HL
test, P <0.01 for all scores, Table 2). By analysis of AUC,




Number (%) Mortality rate up to six mont
0 to 2 34 (25.0%) 3%
3 to 4 38 (27.9%) 21%
5 to 6 26 (19.1%) 46%
≥7 38 (27.9%) 84%
Total 136 (100.0%) 40%
PSEP 81%a
aThe 95% CI could not be calculated. CI, confidence interval; ECMO, extracorporeal
Medical Center Regensburg.the SOFA and ECMOnet score (P = 0.03 and P = 0.01,
respectively, Table 2, Figure 1). However, it did not im-
prove discrimination compared to the PRESERVE score
(P = 0.12).
Model 2
Addition of day-1 parameters resulted in a predictive
model based on eight variables (Table 4). Model 2 showed
good predictive ability, acceptable discrimination and
adequate goodness-of-fit (Table 2). The calibration plot
showed good agreement between predicted and observed
probability (Additional file 5). The shrinkage factor was
0.87. Model 2 had significantly better predictive ability
than Model 1 (LR-test: P <0.001) and showed enhanced
discrimination (Figure 1) compared both to Model 1 and
the PRESERVE score (P = 0.03 and P = 0.003, respectively).
In a separate nested analysis (n = 236), Model 2 (AUC:
0.794 (0.736 to 0.853)) also showed a better discriminative
ability compared to the SOFA (AUC: 0.588 (0.512 to 0.665)),
ECMOnet (AUC: 0.609 (0.536 to 0.683)) and PRESERVE
(AUC: 0.699 (0.629 to 0.768)) scores calculated using day
1 data (P <0.001, P <0.001 and 0.01, respectively).
Classification of patients into three respective risk groups
revealed good agreement between mean predicted and
observed group mortality risks for both Models 1 and 2
(Table 5).d validation cohorts
UKR ECMO registry






53% (95% CI 37–69)
membrane oxygenation; PSEP, prognostic separation index; UKR, University
Table 4 Novel mortality prediction models for ALF-patients re
Coefficien
Model 1 (pre-ECMO)
Age (per five years) 0.176
Immunocompromised state 0.958
Minute ventilation (L/minute) 0.098
Pre-ECMO hemoglobin (g/dL) −0.182
Pre-ECMO lactate (mmol/L) 0.013
Intercept −2.083
Model 2 (Day 1)
Age (per five years) 0.184
Immunocompromised state 1.093
Minute ventilation (L/minute) 0.137
Pre-ECMO hemoglobin (g/dL) −0.208
Day 1 FiO2 (per 10%) 0.264
Day 1 fibrinogen (mg/dL) −0.002
Day 1 norepinephrine (μg/minute/10 kg) 0.159
Day 1 C-reactive protein (mg/L) −0.004
Intercept −1.893
ALF, acute lung failure; CI, confidence interval; ECMO, extracorporeal membrane ox
Figure 1 Comparison of the receiver-operating curves for all
risk prediction tools (n = 241). Neither the ECMOnet nor the
PRESERVE score had significantly better discrimination compared to
the SOFA score (P= 0.67 and 0.25, respectively). Model 1 improved
discrimination compared to the SOFA and the ECMOnet score (P= 0.03
and 0.009, respectively). Addition of parameters available one day after
ECMO initiation further enhanced discrimination compared to both
Model 1 and the PRESERVE score (P= 0.03 and P= 0.003, respectively).
Further statistical comparison is given in Table 2. ECMO, extracorporeal
membrane oxygenation; SOFA, Sequential Organ Failure Assessment.
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In this large study regarding mortality prediction in ALF
patients with vvECMO support, we found that both
the PRESERVE and ECMOnet score were suboptimal
to predict mortality accurately in our population. Two
novel risk models were developed showing improved
predictive ability. The addition of parameters available
the first day after ECMO initiation enhanced mortality
prediction. The combination of predictors found to be
associated with the most optimal risk prediction in this
study add evidence to the hypothesis that high comorbid-
ity and unresponsive respiratory failure are important
determinants of mortality following vvECMO support.
Pre-existing tools for predicting mortality
The SOFA score was designed for and has become
well-integrated in clinical practice as an easily available
bedside tool to evaluate organ failure/dysfunction over
time in ICU patients. As recently described, a high pre-
ECMO SOFA score has been associated with a higher
mortality risk [13].
The ECMOnet score is an additive score (range 0 to 10)
based on baseline characteristics of 60 patients with severe
ARDS due to suspected or confirmed H1N1-influenza
virus infection [6]. In our study population, the ECMOnet
score did not show better discrimination than the SOFA
score. Comparison of original and recalibrated estimates
revealed considerable differences between the study popu-
lations, but continued poor discrimination after recalibra-
tion indicated that the combination of predictors was notceiving ECMO support
t OR 95% CI
1.193 (1.148 to 1.239)
2.605 (1.316 to 5.158)
1.103 (1.014 to 1.199)
0.834 (0.728 to 0.954)
1.013 (1.004 to 1.023)
1.202 (1.148 to 1.258)
2.984 (1.394 to 6.391)
1.147 (1.030 to 1.276)
0.812 (0.696 to 0.947)
1.302 (1.232 to 1.376)
0.998 (0.996 to 0.999)
1.172 (0.980 to 1.401)
0.996 (0.992 to 0.999)
ygenation; FiO2, fraction of inspired oxygen; OR, odds ratio.
Table 5 Clinical validation of novel mortality scores
Predicted risk N Mean predicted risk Observed mortality risk Clinical validation PSEP (95% CI)
Model 1 57 (31 to 84)
<40% 159 22.7% 24.5% 75.5%a
40% to 80% 114 56.2% 54.5%
>80% 11 86.6% 81.8% 81.8%b
Total population 38.7%
Model 2 61 (43 to 80)
<40% 148 15.7% 19.6% 80.4%a
40% to 80% 94 56.9% 57.4%
>80% 21 87.1% 81.0% 81.0%b
Total population 38.0%
aNegative predictive value for the low-risk group (<40%). bPositive predictive value for the high-risk group (>80%). CI, confidence interval; n, number of patients in
risk group; PSEP, prognostic separation index.
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been externally validated twice in patient populations with
a similar profile as the original study [6,14]. Recent results
indicate that patients receiving ECMO due to influenza-
A virus infection have a lower mortality than patients
presenting with other causes of ALF [13]. In addition,
the ECMOnet study excluded patients with pre-ECMO
mechanical ventilation >7 days, leaving a patient population
that may have a more favorable risk profile [4]. Although a
more homogenous study population improves performance
and stability of a risk prediction model, this may also limit
its general applicability.
The PRESERVE score was developed in a multicenter
study comprising 140 patients with severe ARDS. The
additive score (range 0 to 12) consists of eight predictors.
To our knowledge, this study is the first to externally
validate the score. Minimal differences in predictor distri-
butions as well as similar overall mortality rates support
the comparability of the original and validation study
populations. There was a clear linear trend in the risk
of mortality across increasing subgroups of PRESERVE
score. However, the observed differences in the subgroup
mortality rates and the reduction in PSEP may be related
to overfitting from the original analysis [11]. Again, in our
population the PRESERVE score did not show better
discrimination than the SOFA score.
Novel risk models
Based on the confirmed usefulness of the established
scores, we identified three strengths in our study which
justify our attempt to develop a new risk model: First, the
present study (n = 304) is the largest study investigating
mortality prediction in ALF patients receiving vvECMO
support. Second, the availability of a broad range of vari-
ables potentially related to ECMO outcome increases
the chances of finding an improved combination of pre-
dictors for mortality following vvECMO. Third, the rigorof variable selection and the statistical methods applied
have been designed to avoid overfitting the models to the
study population [15-17].
The final models described in the present study represent
combinations of variables that contain the most useful
information to predict ECMO mortality. The models are
not designed to reflect causal relationships between single
predictors and outcome, which would only be possible
if all factors that influence mortality were known. The
included predictors may not play causal roles themselves,
but carry information from one or several other predictors
and thus represent markers for other causal relationships.
The composition of predictors in Models 1 and 2 under-
line the importance of the patient’s underlying health
condition and regenerative capacity for prediction of
ECMO outcome. Advanced age and chronic immuno-
suppression, both associated with reduced functional
reserves, high comorbidity and reduced ability to recover,
have been consistently associated with increased mortality
[7,9,18]. In accordance with previous findings, we found
the necessity of high minute ventilation before ECMO
to be an important predictor of mortality [9]. A high
pre-ECMO serum lactate concentration could indicate
tissue hypoxia with subsequent metabolic acidosis and
severe organ injury. Parallel to reduced hematocrit
described in the ECMOnet study, low pre-ECMO
hemoglobin concentrations were associated with an
increased mortality risk. Possible causes of pre-ECMO
anemia include hospital-acquired anemia, iron defi-
ciency anemia or chronic disease. Preoperative anemia
has repeatedly been described as an independent risk
factor for increased mortality in cardiac as well as
noncardiac surgery [19,20]. The harmful effect of
anemia is greater than the increased risk explained by
the need for transfusion [20]. Thus, associated comor-
bid conditions may confound the role of anemia as a
risk factor.
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that ECMO relieves patients from acute respiratory and
hemodynamic stress and provides time to recover already
within the first 24 hours. In patients with severe hypox-
emia or high cardiac output, where ECMO may not
improve gas exchange sufficiently to decrease aggres-
siveness of mechanical ventilation, continued invasive
ventilation with high volume and FiO2 may bring about a
vicious cycle with ventilator-induced lung injury [4]. Thus,
sparse reduction or continued need for a high FiO2 and
norepinephrine on day 1 may indicate patients with unre-
sponsive respiratory failure despite ECMO.
Furthermore, day 1 plasma concentrations of fibrinogen
and C-reactive protein (CRP) were identified as important
predictors of ECMO outcome. Surprisingly, low CRP was
associated with increased risk of mortality. This might be
related to the ability to activate the immune system in
order to defend against on-going infection and trigger
recovery mechanisms. Whereas survivors generally had
higher CRP before and one day after ECMO implantation,
they had lower CRP concentrations post-ECMO, leading
to the hypothesis that survivors were able to quickly acti-
vate an effective immune response. The lower CRP in
non-survivors, on the other hand, might indicate immune
exhaustion or liver failure, with a failing attempt to bring
about an effective response in order to establish control of
their acute illness.
The protective effect seen with higher fibrinogen con-
centrations may have several explanations. First, it may
be another sign of an effective immune response, supported
by the role of fibrinogen as an acute phase reactant. Given
that both fibrinogen and CRP remained significant, they
both provide information in addition to that from the other
factor, even if the two may be somewhat correlated. Second,
low fibrinogen levels are also associated with bleeding dis-
orders, large-volume blood transfusions and disseminated
intravascular coagulation, which are all associated with
higher mortality. Fibrinogen may thus be an inform-
ative marker replacing the need for many individual
markers and may contain information from several
functions that affect outcome following ECMO support.
All together, the parameters from Model 2 enhanced dis-
crimination between patients with high regenerative capacity
and reversible disease from those with poor health condi-
tion, reduced functional reserves and intractable illness.
Challenges related to mortality prediction in vvECMO
patients
This study illustrates the difficulties in creating a ro-
bust model for predicting mortality following vvECMO.
Model 1 showed improved goodness-of-fit and somewhat
improved discrimination; however, the discriminative abil-
ity was not significantly enhanced from the PRESERVE
score. ECMO patients have a large heterogeneity in diseaseand health conditions, and behind ‘mortality of all causes’
there is a large diversity in underlying causality. Patients
have different diagnoses, time courses, ages, comorbidities,
different sites and types of infection, and different degrees
of physiological dysfunction [21]. Therefore, inclusion of
day1 parameters seemed a promising approach to better
prediction. The external scores calculated on day 1 data
did not provide adequate risk prediction, supporting
the usefulness of our new model.
It would be of interest to develop a prediction model for
use later during the course of ECMO, for example on day
7. Such a model might aid in the decision to wean the
patient from ECMO. However, due to smaller patient
numbers caused by earlier weaning or death, a preliminary
day 7 model for the remaining 193 patients (126 survivors
and 67 non-survivors) showed wide CIs for the odds ratios
and was not significantly better at predicting mortality
than the day 1 model (P = 0.25, data not shown). Thus, it
seems that a substantially larger study would be needed.
Furthermore, any model aimed at predicting withdrawal
of futile therapy has to be extremely accurate in order
not to lead to erroneous decisions. From our present
experience with 350 patients, we have observed previously
unthought-of capacities of injured lungs to recover.
In this study, different statistical approaches were ex-
plored and compared in order to derive the best and most
robust prediction model. While previous models have
based their variable selection on univariate analyses, we
employed a method combining clinical experience and
judgment with computer-based statistics. Nevertheless,
the inhomogeneous study population makes overfitting a
persisting challenge and the ability of a predictive model
to estimate the prognosis of individual patients with high
accuracy remains limited. The usefulness of a prediction
model rather lies in the assistance it may provide for the
discrimination between higher- and lower-risk patients in
order to help identify potential candidates for ECMO sup-
port and give guidance for rational and ethical resource
utilization [6,11]. We, therefore, categorized patients into
three groups with significantly different probabilities of
survival. It may be argued that our defined high-risk group
was very small, but we kept this cut-off because of its
potential clinical usefulness. Categorization of patients may
also be helpful for future external and internal validations
in order to compare institutional variations in indications
and practice of ECMO. However, although the risk score
may function as a useful supplementary tool for clinicians,
thorough clinical evaluation on a case-to-case basis still
remains the cornerstone of ECMO handling.
Study limitations
Conventional rescue therapies, such as prone positioning
and use of neuromuscular blockade, were not registered
in all patients in the UKR database. A part of our study
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prone positioning were not universally accepted and
neuromuscular blockade was only rarely used in Germany.
Hence, the quality of conventional treatment which may
be associated with mortality irrespective of the other
factors included in the model could not be evaluated in
this study. In the calculation of the PRESERVE scores, all
patients were assigned to ‘no prone positioning pre-ECMO.’
However, this may contribute to overestimating mortality
risk with PRESERVE in our patient population. Further-
more, the PRESERVE score used mortality six months
post-ICU discharge as the end-point, while the present
study only followed patients up to hospital discharge.
Mid- and long-term outcomes are important in ARDS
patients receiving vvECMO support. Unfortunately, in
the past, long-term outcomes of our patients and health-
related quality of life were not reevaluated, as many
patients were retrieved from distant hospitals after our
team implanted ECMO as a rescue procedure to allow
transport to our center. We plan to carry out a follow-up
study to evaluate the validity of the presented models in
the prediction of mid- and long-term mortality.
Missing observations due to incomplete documentation
for some laboratory and respiratory parameters reduced
the effective sample size in the statistical analyses. Bias
due to cohort selection or missing data in the presented
analyses seems unlikely since the overall mortality rate
was constant in all subsamples with complete information
for the different parts of the study. Since validation
through bootstrap methods is preferred over data splitting
methods [17], we used the whole patient cohort for model
development. However, external validation is a crucial step
before these models can be applied in clinical practice.
Conclusions
Pre-existing tools for predicting outcome following vvEC
MO in patients with ALF have been of limited usefulness.
The present study provides two novel risk models designed
to help assist in defining treatment decision and further
handling of ECMO. Markers of associated comorbidity,
a poor pre-ECMO health condition and unresponsive
respiratory failure were consistently associated with in-
creased mortality. Mortality prediction improved the day
following ECMO initiation, when ECMO has reduced acute
stress and provided time to rest. Nevertheless, due to high
variability among patients, predictive models can only act
as supplementary tools and do not replace the role of clin-
ical evaluation for indication and continuation of ECMO.
Key messages
 Established risk assessment tools for adult patients
with severe acute lung failure on vvECMO are of
limited usefulness. Large patient heterogeneity makes generalized
pre-ECMO mortality prediction a persisting
challenge, despite use of robust statistical methods.
 Addition of variables measured one day after ECMO
initiation improves mortality prediction.
 Risk prediction tools function as a useful supplement
to guide clinical decision-making, although clinical
evaluation remains the cornerstone of ECMO practice.
Endnote
aAvailable at: http://www.r-project.org. Accessed June
15, 2013.
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